Digital download
Access the files immediately after checkout.
Lantheus Medical Imaging Marketing Mix
Included with this resource
Word + Excel files
Edit, adapt and present the analysis in familiar formats.
Complete marketing mix
Connect product, price, place and promotion.
Customer perspective
Review how each decision supports the target market.
Actionable choices
Turn the mix into practical marketing priorities.
Get Inspired by a Complete Brand Strategy
Lantheus Medical Imaging’s product innovation, pricing tiers, distribution partnerships, and targeted promotion combine to sustain its diagnostic imaging leadership; our concise 4P summary highlights these synergies and market leverage. Get the full, editable 4Ps Marketing Mix Analysis for data-driven insights, ready-to-use slides, and strategic recommendations to apply immediately.
Product
Radiopharm portfolio
Radiopharm portfolio centers on PET and SPECT imaging agents across cardiology, oncology and neurology, plus select therapeutics; flagship tracer PYLARIFY was FDA-approved in 2021 and drives oncology use. These products deliver high clinical sensitivity and specificity to inform diagnosis and treatment planning. Differentiation rests on clinically validated tracers, predictable supply chains and regulatory-approved indications. Ongoing pipeline expansions and label enhancements sustain lifecycle value.
Oncology PET tracers
PSMA-targeted PET agents like PYLARIFY (FDA approved 2021) enable precise prostate cancer detection, staging and treatment monitoring, with reported detection rates up to 85% in biochemical recurrence cohorts. High image quality supports theranostic pathways and selection for targeted radioligand therapy. NCCN and EAU guideline inclusion has accelerated clinical adoption, while Lantheus provides companion interpretation and workflow tools to streamline use.
Cardiac imaging agents
SPECT perfusion agents from Lantheus support evaluation of ischemia and myocardial function, with SPECT accounting for over 70% of global nuclear cardiology studies. Consistent image quality, validated protocols and dosing flexibility accommodate diverse patient profiles and body habitus. Products integrate with standard gamma cameras and workflows to boost throughput, while education and technical support help lower inter‑site variability in image interpretation.
Ultrasound contrast
Microbubble agents enhance cardiac and hepatic imaging where native echogenicity is limited, improving lesion and endocardial border detection; compatible with over 95% of commercial ultrasound systems and offering rapid preparation that boosts departmental throughput. Robust post-market safety data and growing adoption in 2024 support routine use, while vendor training optimizes parameters and interpretation.
- Enhances cardiac/hepatic visualization
- Broad system compatibility (>95%)
- Rapid prep improves efficiency
- Established safety and training support
Services and support
Services and support combine clinical education, applications support, and pharmacovigilance to optimize imaging agent performance and safety, backed by 24/7 technical support. Ordering portals and compliance resources streamline operations and reduce administrative friction. Evidence summaries and reimbursement guidance accelerate adoption while collaborative multi-center studies expand real-world data.
- 24/7 tech support
- Clinical education programs
- Reimbursement & evidence summaries
- Collaborative real-world studies
PSMA PET and SPECT: detection up to 85%, SPECT > 70%
Radiopharm portfolio centers on PET/SPECT agents across cardiology, oncology and neurology; flagship PYLARIFY (FDA 2021) drives PSMA PET adoption. PSMA PET reports detection rates up to 85% in biochemical recurrence; SPECT represents >70% of global nuclear cardiology studies. Microbubble agents are compatible with >95% of ultrasound systems; services include 24/7 tech support and reimbursement guidance.
| Metric | Value |
|---|---|
| PYLARIFY approval | FDA 2021 |
| PSMA detection (biochem recur.) | up to 85% |
| SPECT share (nuclear cardiology) | >70% |
| Microbubble compatibility | >95% |
| Support | 24/7 tech & education |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific deep dive into Lantheus Medical Imaging’s Product, Price, Place, and Promotion strategies, highlighting diagnostics portfolio, pricing dynamics, distribution channels, and promotional tactics. Ideal for managers and consultants needing a practical, data-grounded marketing positioning brief ready for reports or presentations.
Customizable Excel Spreadsheet
Summarizes Lantheus Medical Imaging’s 4Ps into a concise, presentation-ready view that clarifies product positioning, pricing strategy, placement channels, and promotional levers to resolve stakeholder confusion. Ideal for leadership briefings or cross-functional alignment, it speeds decision-making and adapts easily for benchmarking or workshop use.
Place
Nuclear pharmacies
Lantheus leverages national and regional nuclear pharmacy networks for dose compounding and last-mile delivery to ensure reliable availability aligned with imaging schedules. Standardized processes support quality and regulatory compliance with NRC requirements and USP 797 sterile compounding standards. Proximity to hospitals minimizes tracer decay risk, critical given F-18 half-life of ~110 minutes and Tc-99m half-life of ~6 hours.
Direct to hospitals
Direct shipments supply high-volume imaging centers and IDNs with predictable delivery windows tailored to procedure schedules, supporting same-day and next-day workflows. Cold-chain logistics (typical 2–8°C control) and validated packaging preserve radiopharmaceutical integrity. Electronic ordering with forecasting aligns inventory to case mix, and service-level agreements target 99% uptime and rapid responsiveness.
PET manufacturing hubs
Partner cyclotrons and regional manufacturing nodes enable Lantheus to produce PET tracers just-in-time, critical given F-18 half-life 110 minutes and Ga-68 68 minutes. Geographic dispersion shortens transit, preserving activity for clinical use. Capacity planning balances demand surges and maintenance windows, while hub redundancy mitigates supply disruptions.
Global footprint
Commercial reach is concentrated in the U.S. with selective international distribution and licensing partnerships; market access outside the U.S. is driven by local regulatory approvals and tender processes. Country-specific labeling and training programs support safe, compliant use in each market. Strategic partnerships and distributors accelerate entry and scale across regions.
- U.S.-focused distribution
- Regulatory/tender-dependent access
- Local labeling & training
- Partnerships speed market scale
Inventory and compliance
Forecasting tools synchronize doses with scheduled patients to limit waste; GDP-compliant cold-chain and chain-of-custody controls ensure full traceability. Automated alerts manage expiries and deviations, reducing stockouts and regulatory risk. Integration with hospital systems eases reconciliation and audits.
- Forecasting: dose-to-schedule alignment
- Traceability: GDP cold-chain + chain-of-custody
- Alerts: expiries/deviations
- Integration: hospital reconciliation & audits
Regional nuclear pharmacies enable same-day imaging with 99% uptime and cold-chain control
Lantheus uses regional nuclear pharmacies, partner cyclotrons and direct shipments to support same-day/next-day imaging with 99% target uptime, GDP 2–8°C cold-chain, and NRC/USP 797 compliance; proximity reduces decay risk (F-18 110 min, Ga-68 68 min, Tc-99m 6 hr).
| Metric | Value |
|---|---|
| Uptime target | 99% |
| F-18 half-life | 110 min |
| Cold-chain | 2–8°C |
What You See Is What You Get
Lantheus Medical Imaging 4P's Marketing Mix Analysis
The Lantheus Medical Imaging 4P's Marketing Mix Analysis you see here covers Product, Price, Place and Promotion with targeted insights and recommendations tailored to the company’s portfolio and market dynamics. This preview is the exact, final document you’ll receive immediately after purchase—fully complete and ready to use.
Promotion
Clinical evidence
Peer-reviewed studies, multicenter registries, and guideline inclusion drive physician confidence in Lantheus imaging agents, notably following FDA approval of Pylarify in 2021. Data emphasize diagnostic accuracy and downstream management impact across clinical settings. Health-economic analyses published through 2024 support payer value narratives. Ongoing publication planning sustains visibility and evidence uptake.
KOL engagement
Advisory boards and investigator-initiated research have built champions across cardiology, oncology, and nuclear medicine, engaging dozens of KOLs to drive clinical uptake; speaker programs and case reviews translate evidence into practice, reaching hundreds of clinicians annually. Site-of-care education has reduced protocol variability by an estimated 20–30%, while continuous feedback loops from investigators inform iterative product refinements and downstream commercial strategy.
Congress presence
Active participation at RSNA, SNMMI, ACC, ASCO and EANM elevates Lantheus Medical Imaging brand awareness through targeted symposia and hands-on workshops that teach imaging best practices. Booth demonstrations emphasize workflow efficiency and interpretation tips to support clinical adoption. Scientific exchange at these congresses follows FDA and PhRMA promotional compliance and company policies.
Digital medical education
Market access outreach
Market access outreach leverages payer briefings, dossier submissions, and HEOR summaries to secure coverage and coding; field reimbursement teams support prior authorization and claims resolution, reducing claims denial rates and administrative delays. Customer contracts are structured to align with GPOs and IDNs (majority use ≈80%), while patient education materials clarify imaging value and care pathways.
- Payer briefings, dossiers, HEOR → coverage/coding
- Field reimbursement → prior auth & claims support
- Contracts aligned with GPOs/IDNs (≈80% market participation)
- Patient materials → adherence & pathway clarity
HEOR drove uptake: >10,000 learners; variability ↓ ~25%
Peer-reviewed evidence (Pylarify FDA 2021) and HEOR through 2024 drove clinician uptake; digital education enrolled >10,000 learners (2024–2025) and reduced protocol variability ~25%. Advisory boards engaged dozens of KOLs; congress programs (RSNA, SNMMI, ACC, ASCO, EANM) sustain visibility. Payer outreach and field reimbursement support align with GPO/IDN contracts covering ≈80% sites.
| Metric | Value |
|---|---|
| Learners (2024–25) | >10,000 |
| Protocol variability↓ | ~25% |
| GPO/IDN participation | ≈80% |
Price
Value-based pricing
Value-based pricing for Lantheus links price to clinical utility, diagnostic accuracy, and downstream cost offsets from better decisions; economic models (2024) show up to 20% fewer avoidable procedures and measurable therapy-optimization savings. Alignment with ACR/EANM guidelines strengthens perceived value and reimbursement. Periodic price reviews adjust to new evidence and competitive dynamics.
Reimbursement alignment
Coding guidance and HCPCS/APC support from Lantheus align with CMS annual HCPCS updates to enable predictable provider payment. Site tools document medical necessity and appropriate use criteria to support claims. Ongoing monitoring of Medicare and private payer policy changes mitigates revenue risk. Active collaboration with professional societies such as SNMMI informs targeted advocacy.
Contracting strategy
Tiered pricing through GPOs and IDNs rewards volume and formulary placement, leveraging that GPOs serve over 97% of U.S. hospitals to drive scale. Bundled service packages add training and ongoing support, often including 24/7 technical assistance. Multi-year agreements (typically 3–5 years) give budget certainty for large centers. Transparent terms reduce administrative burden and speed procurement cycles.
International tenders
International tenders for Lantheus are priced against reference-country benchmarks and tender ceilings, with FY2024 revenues of roughly $1.09 billion guiding global pricing strategy; bids reflect local cost structures and logistics to protect margins. Outcome and real-world evidence increasingly improve tender competitiveness in 2024–2025 procurement decisions, while strict adherence to country-specific procurement rules ensures eligibility.
- FY2024 revenue ~ $1.09B
- Tender pricing tied to reference pricing and local costs
- Outcome data raises competitiveness in 2024–2025 procurements
- Compliance with country rules required for eligibility
Access and affordability
Patient assistance and site support programs reduce financial barriers through targeted copay support and site grants, improving access for underinsured patients. Flexible delivery scheduling minimizes product waste and lowers cost per scan, while starter kits and trial pricing speed new-site onboarding. Periodic audits preserve pricing integrity and regulatory compliance.
- Patient assistance: targeted copay/site grants
- Logistics: flexible delivery to cut waste
- Onboarding: starter kits + trial pricing
- Compliance: regular pricing audits
Value-based pricing: up to 20% fewer procedures, backed by $1.09B FY2024 revenue
Value-based pricing ties price to clinical utility and downstream savings; 2024 models show up to 20% fewer avoidable procedures. FY2024 revenue ~$1.09B anchors global tender and reference pricing. GPO/IDN tiering (GPOs cover ~97% of US hospitals) and 3–5 year contracts provide scale and budget certainty. Patient copay assistance and starter-trial pricing improve access and onboarding.
| Metric | 2024/2025 Value |
|---|---|
| FY2024 revenue | $1.09B |
| Avoidable procedures reduction | Up to 20% |
| GPO hospital coverage | ~97% |
| Contract length | 3–5 years |